Rosella Levaggi

Scopus Author ID ResearcherID ORCID

Publication Activity (10 Years)

Years Active: 2016-2024
Publications (10 Years): 17

Top Venues

Expert review of pharmacoeconomics & outcomes research

Pharmacy (Basel, Switzerland)

Health economics

Bioanalysis

University of Brescia

University of York (MSC)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

University of Brescia Nov 01 2001

Italy

Chair in Public Economics :: Department of Economics and Management

Education History

University of York Oct 01 1986 - Jul 01 1987

United Kingdom

MSC :: Department of Economics

Publications

Laura Levaggi, Rosella Levaggi
Timely, Cheap, or Risk-Free? The Effect of Regulation on the Price and Availability of New Drugs. Pharmacy (Basel, Switzerland) 12 (2) (2024)
Laura Levaggi, Rosella Levaggi
Timely, Cheap, or Risk-Free? The Effect of Regulation on the Price and Availability of New Drugs. Pharmacy (Basel, Switzerland) 12 (2) (2024)
Laura Levaggi, Rosella Levaggi
Timely, Cheap, or Risk-Free? The Effect of Regulation on the Price and Availability of New Drugs. Pharmacy (Basel, Switzerland) 12 (2) (2024)
Stefano Capri, Fernando Antoñanzas, Rosella Levaggi
The impact of conventional cost-effectiveness analysis on pricing dynamics in the market of new medicines: a proposed countervailing approach. Expert review of pharmacoeconomics & outcomes research (2023)
Stefano Capri, Fernando Antoñanzas Villar, Rosella Levaggi
The impact of conventional cost-effectiveness analysis on pricing dynamics in the market of new medicines: a proposed countervailing approach. Expert review of pharmacoeconomics & outcomes research 23 (4) (2023)
Stefano Capri, Fernando Antoñanzas Villar, Rosella Levaggi
The impact of conventional cost-effectiveness analysis on pricing dynamics in the market of new medicines: a proposed countervailing approach. Expert review of pharmacoeconomics & outcomes research 23 (4) (2023)
Stefano Capri, Fernando Antoñanzas Villar, Rosella Levaggi
The impact of conventional cost-effectiveness analysis on pricing dynamics in the market of new medicines: a proposed countervailing approach. Expert review of pharmacoeconomics & outcomes research (2023)
Simona Giulia Signorini, Duilio Brugnoni, Rosella Levaggi, Emirena Garrafa
Less is more: an ecological and economic point of view on appropriate use of lab testing for COVID-19 patients. Bioanalysis 13 (24) (2021)
Rosella Levaggi, Paolo Pertile
A reply to "Who would benefit from average value-based pricing?" Health economics 30 (9) (2021)
Lucia Leporatti, Rosella Levaggi, Marcello Montefiori
Beyond price: the effects of non-financial barriers on access to drugs and health outcomes. The European journal of health economics : HEPAC : health economics in prevention and care 22 (4) (2021)
Rosella Levaggi, Paolo Pertile
Value-Based Pricing Alternatives for Personalised Drugs: Implications of Asymmetric Information and Competition. Applied health economics and health policy 18 (3) (2021)
Emirena Garrafa, Duilio Brugnoni, Mosè Barbaro, Laura Andreoli, Emanuele Foca', Massimo Salvetti, Francesco Castelli, Franco Franceschini, Simone Piva, Maria Lorenza Muiesan, Nicola Latronico, Rosella Levaggi
Laboratory considerations amidst the coronavirus disease 2019 outbreak: the Spedali Civili in Brescia experience. Bioanalysis 12 (17) (2020)
Joan Costa-Font, Rosella Levaggi
Innovation, aging, and health care: Unraveling "silver" from "red" herrings? Health economics (2020)
Rosella Levaggi, Paolo Pertile
Authors' Reply to Garattini and Freemantle: "Value-Based Pricing Alternatives for Personalised Drugs: Implications of Asymmetric Information and Competition". Applied health economics and health policy 18 (3) (2020)
Rosella Levaggi, Paolo Pertile
Which valued-based price when patients are heterogeneous? Health economics 29 (8) (2020)
Laura Levaggi, Rosella Levaggi
Rationing in health care provision: a welfare approach. International journal of health economics and management (2016)
Laura Levaggi, Rosella Levaggi
Devolution and grant-in-aid design for the provision of impure public goods. SpringerPlus 5 (2016)

Rosella Levaggi.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Rosella Levaggi